Dear AuntMinnie Member,
Have you signed up yet for our Spring 2022 Virtual Conference: AI, Women's Health, and More? It takes place March 30-31, and we've got a great lineup of key opinion leaders ready to discuss the technologies that are shaping radiology today -- and in the future.
From Dr. Melissa Chen's talk on the economics of artificial intelligence (AI) for women's health to Dr. Nina Kottler's presentation on implementing AI across a large-scale enterprise, you'll find a wealth of knowledge in a unique interactive format. Other speakers include Dr. Manisha Bahl, Dr. Linda Moy, Dr. Eliot Siegel, and Dr. Jesse Courtier, as well as talks from our corporate partners.
So reserve your seat now and register for free today!
New prostate treatment
An exciting new treatment for prostate cancer was approved by the U.S. Food and Drug Administration (FDA) this past week. The product is a lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy from Novartis called Pluvicto, and it's indicated for adult patients with PSMA-positive castration-resistant prostate cancer.
The FDA's move is being applauded by advocates of molecular imaging like the Society of Nuclear Medicine and Molecular Imaging, which notes that the new therapy relies on PET scans to identify and treat patients whose metastatic prostate cancers express PSMA.
While you're in our Molecular Imaging Community, check out a story on how a metabolic pattern on brain PET images indicates the presence of long COVID-19 in patients, and how PET can be used to improve predictions of survival in patients with prostate cancer.
Get these stories and more in our Molecular Imaging Community.
COVID and cancer screening
Finally, another study came out in the past week with disturbing findings on the impact of COVID-19 on cancer screening. The lower screening rates that occurred during the pandemic could lead to higher death rates in the future, researchers found.
